SD Biotechnologies
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SD Biotechnologies makes sheet face masks, eye patches, and everyday skincare products under its SNP and SNP Prep brands, and also supplies a compact, concentrated broth product for home cooking under its food brand.
Its cosmetics products reach both domestic South Korean consumers and international markets, while its food line targets the domestic online retail channel. Listed on KOSDAQ, South Korea's tech and small-cap board, the company operates two distinct business segments, cosmetics and food, with cosmetics, centred on face masks and eye patches, forming the core of its activity.
Summary is AI-generated and may contain errors · figures from DART filings
SD Biotechnologies in five facts
What does SD Biotechnologies do?
SD Biotechnologies makes sheet face masks, eye patches, and everyday skincare products under its SNP and SNP Prep brands, and also supplies a compact, concentrated broth product for home cooking under its food brand.
Where is SD Biotechnologies listed and in which sector?
SD Biotechnologies (Korean name: 에스디생명공학) trades under KRX code 217480 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is SD Biotechnologies?
Its market capitalisation was US$41.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SD Biotechnologies's latest annual revenue and operating profit?
For fiscal year 2025, SD Biotechnologies reported revenue of US$22.7M, an operating loss of US$4.8M and a net loss of US$5.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 12.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureOct 7
- [Amended] Resolution to convene a general shareholders' meetingOct 7
- Other market noticeOct 7
- Trading suspensionOct 7
- Other management matter (voluntary)Oct 7
- [Amended] Notice of general shareholders' meetingOct 7
- Trading suspension liftedOct 6
- Other market noticeOct 6
- Notice of general shareholders' meetingSep 30
- [Amended] DisclosureSep 23
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 23
- Other market noticeSep 3
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 21
- Completion report on merger, etc. (asset transfer)M&A · Mar 16
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 19
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SD Biotechnologies reported consolidated results for FY2025: revenue of US$20.6M (−12.8% year on year), an operating loss of US$4.32M and a net loss of US$5.12M.
Earnings · Feb 9